Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $20.33 Average Price Target from Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has received an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $20.3333.

Several research analysts have weighed in on ENTA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, January 21st. JPMorgan Chase & Co. began coverage on shares of Enanta Pharmaceuticals in a report on Friday, November 14th. They issued an “overweight” rating and a $17.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 10th.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of institutional investors have recently modified their holdings of ENTA. Meeder Asset Management Inc. purchased a new position in Enanta Pharmaceuticals during the 4th quarter valued at about $32,000. Seven Fleet Capital Management LP purchased a new stake in Enanta Pharmaceuticals during the fourth quarter worth about $36,000. Strs Ohio acquired a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth about $50,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Enanta Pharmaceuticals by 333.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock worth $57,000 after buying an additional 2,758 shares in the last quarter. Finally, Quarry LP purchased a new position in Enanta Pharmaceuticals in the 3rd quarter valued at approximately $81,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Stock Up 1.6%

Shares of Enanta Pharmaceuticals stock opened at $14.17 on Monday. The firm has a market cap of $411.21 million, a PE ratio of -4.43 and a beta of 0.96. Enanta Pharmaceuticals has a 52 week low of $4.09 and a 52 week high of $17.15. The business’s fifty day simple moving average is $13.66 and its 200-day simple moving average is $12.31.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.12. The firm had revenue of $18.62 million during the quarter, compared to the consensus estimate of $16.14 million. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%. As a group, equities analysts expect that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.